Whole-Exome Profiling of NSCLC Among African Americans

Arauz, Rony F.; Byun, Jung S.; Tandon, Mayank; Sinha, Sanju; Kuhn, Skyler; Taylor, Sheryse; Zingone, Adriana; Mitchell, Khadijah A.; Pine, Sharon R.; Gardner, Kevin; Pérez‐Stable, Eliseo J.; Nápoles, Anna María; Ryan, Bríd M.

doi:10.1016/j.jtho.2020.08.029

Cited by 22 publications

(19 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Certain mutations, such as those in STK11, can also open up new avenues of targeted therapies and may be detected with IHC [314,315]. It is noteworthy that the frequency of STK11 mutations in NS-NSCLC patients seems to be lower (4% in Asians) or higher (25% in African Americans) according to the populations, and comparative to the incidence observed in Caucasians (around 14%) [53,316,317]. To detect genomic alterations in fibroblast growth factor receptor (FGFR), biomarkers have been developed but their therapeutic application is still preliminary and concerns mostly squamous cell carcinomas of the lung [318][319][320][321][322].…”

Section: Others Potential Biomarkers Of Interestmentioning

confidence: 98%

What Is New in Biomarker Testing at Diagnosis of Advanced Non-Squamous Non-Small Cell Lung Carcinoma? Implications for Cytology and Liquid Biopsy

Hofman

2021

JMP

View full text Add to dashboard Cite

The discovery and clinical validation of biomarkers predictive of the response of non-squamous non-small-cell lung carcinomas (NS-NSCLC) to therapeutic strategies continue to provide new data. The evaluation of novel treatments is based on molecular analyses aimed at determining their efficacy. These tests are increasing in number, but the tissue specimens are smaller and smaller and/or can have few tumor cells. Indeed, in addition to tissue samples, complementary cytological and/or blood samples can also give access to these biomarkers. To date, it is recommended and necessary to look for the status of five genomic molecular biomarkers (EGFR, ALK, ROS1, BRAFV600, NTRK) and of a protein biomarker (PD-L1). However, the short- and more or less long-term emergence of new targeted treatments of genomic alterations on RET and MET, but also on others’ genomic alteration, notably on KRAS, HER2, NRG1, SMARCA4, and NUT, have made cellular and blood samples essential for molecular testing. The aim of this review is to present the interest in using cytological and/or liquid biopsies as complementary biological material, or as an alternative to tissue specimens, for detection at diagnosis of new predictive biomarkers of NS-NSCLC.

show abstract

Section: Others Potential Biomarkers Of Interestmentioning

confidence: 98%

What Is New in Biomarker Testing at Diagnosis of Advanced Non-Squamous Non-Small Cell Lung Carcinoma? Implications for Cytology and Liquid Biopsy

Hofman

2021

JMP

View full text Add to dashboard Cite

show abstract

“…STK11 mutations are less frequent in Asian (4–7%) than in Caucasian patients (16%) in NSCLC analyzed by the TCGA project [ 96 ]. They were also significantly higher among Afro-American patients [ 97 ]. Interestingly, in one series only 77/1385 (6%) NSCLC patients harbored an STK11 mutation according to next generation sequencing (NGS) analysis while the AACR genie database (v8.1 public) reported STK11 mutations in 1495/14,303 (10.5%) of samples [ 92 ].…”

Section: Stk11 and Associated Genomic Alteratiomentioning

confidence: 99%

The Importance of STK11/LKB1 Assessment in Non-Small Cell Lung Carcinomas

2021

View full text Add to dashboard Cite

Despite the recent implementation of immunotherapy as a single treatment or in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer (NSCLC), many patients do not benefit from this regimen due to primary treatment resistance or toxicity. Consequently, there is an urgent need to develop efficient biomarkers that can select patients who will benefit from immunotherapy thereby providing the appropriate treatment and avoiding toxicity. One of the biomarkers recently described for the stratification of NSCLC patients undergoing immunotherapy are mutations in STK11/LKB1, which are often associated with a lack of response to immunotherapy in some patients. Therefore, the purpose of this review is to describe the different cellular mechanisms associated with STK11/LKB1 mutations, which may explain the lack of response to immunotherapy. Moreover the review addresses the co-occurrence of additional mutations that may influence the response to immunotherapy and the current clinical studies that have further explored STK11/LKB1 as a predictive biomarker. Additionally this work includes the opportunities and limitations to look for the STK11/LKB1 status in the therapeutic strategy for NSCLC patients.

show abstract

“…The inclusion of minority populations has the potential to reveal novel signatures and tumor vulnerabilities, and advance cancer health equity. We previously reported population differences in lung tumor biology, including circulating in ammation proteins, gene expression signatures, somatic mutations, and ancestry-associated single nucleotide polymorphisms [5][6][7][8][9][10][11][12][13][14]. However, work remains to complete the global comparison of tumor biology across racial and ethnic groups.…”

Section: Introductionmentioning

confidence: 99%

Global profiling of alternative splicing in non-small cell lung cancer reveals novel histological and population differences

Zeeshan

Mendelez

Zingone

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Lung cancer is one of the most frequently diagnosed cancers with higher incidence and mortality rates in African-American (AA) men compared to European-American (EA) men. Here, we report high-confidence alternative splicing (AS) events from high-throughput, high-depth total RNA-sequencing of lung tumors and non-tumor adjacent tissues (NATs) from two independent cohorts of patients with adenocarcinoma and squamous cell carcinoma. We uncover tumor subtype- and population-specific AS events different between AAs and EAs, associated with oncogenic signaling pathways, cell surface proteins, and cancer driver genes. We highlight significant AS events in SYNE2 specific to LUAD in both populations as well as those in CD44 from EAs and TMBIM6 from AAs specific to LUAD. Our large survey of lung tumors presents a rich data resource that can help uncover new therapeutic vulnerabilities that potentially advance health equity.

show abstract

Whole-Exome Profiling of NSCLC Among African Americans

Cited by 22 publications

References 64 publications

What Is New in Biomarker Testing at Diagnosis of Advanced Non-Squamous Non-Small Cell Lung Carcinoma? Implications for Cytology and Liquid Biopsy

What Is New in Biomarker Testing at Diagnosis of Advanced Non-Squamous Non-Small Cell Lung Carcinoma? Implications for Cytology and Liquid Biopsy

The Importance of STK11/LKB1 Assessment in Non-Small Cell Lung Carcinomas

Global profiling of alternative splicing in non-small cell lung cancer reveals novel histological and population differences

Contact Info

Product

Resources

About